Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | PPID | Q08752 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17737107 | 1.00 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1CYP2C9CYP2C19HTR2B | |
| SCHEMBL30325030 | 0.84 | TDP1 (0.47) | L3MBTL1ALDH1A1KDM4EPOLBOPRM1 | |
| SCHEMBL3577301 | 0.82 | MEN1 (0.51) | LMNAMAPTRAB9ATDP1 | |
| SCHEMBL14451443 | 0.82 | RORC (0.48) | L3MBTL1ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL25377161 | 0.82 | TP53 (0.45) | L3MBTL1ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL25377167 | 0.82 | TP53 (0.45) | L3MBTL1ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL3577297 | 0.82 | MEN1 (0.51) | LMNAMAPTRAB9ATDP1 | |
| SCHEMBL18971854 | 0.82 | MEN1 (0.51) | LMNAMAPTRAB9ATDP1 | |
| SCHEMBL5523733 | 0.82 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1KDM4ELMNAPOLB | |
| SCHEMBL180554 | 0.82 | IDO1 (0.49) | L3MBTL1ALDH1A1KDM4EMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841478-B2 | Method for preparing trans-{4-[(alkylamino) methyl]- cyclohexyl}acetic acid ester | KOWA COMPANY, LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| US-20110288328-A1 | METHOD FOR PREPARING TRANS-ACETIC ACID ESTER | KOWA COMPANY, LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288328-A1 | METHOD FOR PREPARING TRANS-ACETIC ACID ESTER | ACSL6, ACSL3, ACSL1 | L3MBTL1 1255/4885ALDH1A1 470/4885CYP2C9 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.